Lately, the generics industry has been bashed from all sides with regards to quality, with most of the criticism being directed towards poor Quality-Control standards in Chinese manufacturing facilities. But this month was a terrible …

The Wall Street Journal reported in June that according to Federal Trade Commission Chairman, Jon Leibowitz, originator pharma companies were costing consumers $3.5 billion annually through making contracts with generic companies that delay the market …

This slide by presented by Daniel Hawkins in the MM&M podcast clearly shows why there will soon no longer be a distinction between originator pharma and generic companies. Not many words needed.

You can’t imagine our surprise today when we saw that Pfizer has announced that it will license injectable and solid dosage forms from Aurobindo. We wrote about Pfizer’s new generics strategy on monday, but we …

“If you can’t beat them, join them”. So goes the old saying that is proving more true day-by-day in the pharma industry.  A few years ago it would have been unthinkable that Pfizer, the world’s …